Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

11-04-2024(Thu) 10-04-2024(Wed) 09-04-2024(Tue) 08-04-2024(Mon) 05-04-2024(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
23 Jun, 2020 (Tuesday)

            
XINGYE WULIAN(9916)
Analysis¡G
Xingye Wulian Service Group (9916) a property management service provider in Henan Province with a particular focus on offering property management and value-added services for non-residential properties. Its portfolio of properties under management expanded rapidly during the year ended 31 December 2019, with the gross floor area increased from approximately 1.6 million sq.m. as at 31 December 2018 to approximately 2.4 million sq.m. as at 31 December 2019. As at 31 December 2019, its portfolio of properties under management covered 17 commercial buildings, three governmental buildings and one industrial park. The Group plans to strengthen its position in the property management service industry by taking on additional property management projects with a focus on mid to high-end non-residential properties and selectively pursuing merger and acquisition opportunities within the property management industry. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $1.50, Target Price: $1.70, Cut Loss Price: $1.40


SINO BIOPHARM(1177)
Analysis¡G
The company is a leading company in the Chinese pharmaceutical industry, with a rich product line, focusing on ten therapeutic areas such as liver disease, anti-tumor, analgesia and breathing, and has a wealth of R & D pipeline reserves. Relying on strong R & D capabilities, it is continuously introducing new products, and clinical trials of large quantities of Class 1 new drugs are progressing rapidly (it is estimated that 2 to 3 innovative drugs will be approved for marketing each year after 2021). New varieties will be intensively harvested in the next few years to achieve rapid growth.
Strategy¡G
Buy-in Price: $13.40, Target Price: $15.30, Cut Loss Price: $12.30



FLAT GLASS (6865.HK) - Demand is delayed in the short term, but the medium- and long-term industry boom is expected to continue

Investment Summary

Results Maintained Rapid Growth

Flat Glass recorded a revenue of RMB4,807 million in 2019, up by 56.9% yoy because of the rise of unit price resulting from commission of new production capacity and the recovery of demand. The Company reported net profit attributable to the parent company of RMB717 million, up by 76% yoy; a net cash flow from operating activities of RMB510 million, up by 18.4% yoy; a weighted return on equity of 17%, up by 5% yoy.

Both the Quantity and the Price Increased, with Revenue from PV Glass Accounting for Nearly 80%

In 2019, the sales volume of PV glass of the Company reached 160 million square meters, up by 67% yoy. The gross margin of the Company increased by 5.18 ppts to 32.87% because of the recovering price of PV glass, improvement of production efficiency of the newly-commissioned production capacity and improvement of product mix (thin glass accounted for a higher proportion).

On a closer look, the Company reported revenue of RMB3.75 billion, RMB171 million, RMB451 million and RMB336 million, respectively, from PV glass, float glass, engineering glass and home glass, up by +79%, +9%, +14% and +1% yoy, respectively. Segment gross profit margins was 32.9%, 12.4%, 22% and 28.1%, respectively, which changed by +3.04, -2.83, -2.6 and +0.9 ppts yoy, respectively. The proportion of revenue from PV glass increased to 78%, approaching 80%. Total production capacity increased to 5400 tons/day.

In Q1 2020, the Company recorded a revenue of RMB1,203 million, up by 29.10% yoy and down by 15.6% qoq; net profit of RMB215 million, up by 97.0% yoy and up by 2.6% qoq. Because of the continuance of effect of price yoy lift of PV glass, plus with the low material price, 2020Q1 gross margin continued to hike, reaching a historic height of 39.88%.

In 2019 and Q1 2020, the Company recorded an administration and R&D expense ratio of 6.8% and 5.8%, respectively, down by 0.8 ppts and1.4 ppts yoy, respectively. However, the sales expense ratios were 5.31% and 5.8%, up by 1.12 ppts and 1.25 ppts yoy, respectively, which is mainly because of the increase in transport unit price.

The Pandemic Delay the Demand, but the Prospect of the Industry May Continue in H2

In 2019, domestic PV market tightened, but great performance was reported in overseas market, with export increasing rapidly. Strong overseas momentum was continued in Q1 2020, which compensated the shortage of domestic demand due to domestic suspense of work. In Q2, the delay of overseas demand caused by the pandemic put pressure on the price of PV glass, which may exert some negative impact on the results of the Company in 2020 Q2. However, the revenue from European and American markets only accounted for 10% of the total revenue of the Company. We expected that the demand side will improve steadily from H2 because of the reopen. Looking forward, the PV industry has entered the phase of scale competition. The concentration of the industry continuously roused, and the total market share of the Company and Xinyi Solar has exceeded 50%, which helped the double-oligarchy layout taking shape.

CB and Private placement Will Release the Debt Pressure, and Promotion of Equity Incentives Will Improve Long Term Growth Vitality

In recent years, the Company proactively increased production, which resulted in relatively high pressure on capital expenditure. In the recent three years, capital expenditure reached RMB550 million, RMB1.26 billion and RMB1.3 billion, respectively, and the debt-asset ratio reported 45%, 47%, and 52%, respectively. Recently, the Company announced that it would release convertible bonds of RMB1.45 billion and Private placement of RMB2 billion, which were mainly used in the production and construction of the two 1,200-ton-per-day production lines (Line 4/Line 5), as well the preparation and construction of Line 6/ Line 7 (also 1,200 tons per day) in Fengyang, Anhui. Due to obvious advantages in technology and scale of newly increased capacity, increase in finished production rate and decrease in unit cost will further improve the profitability of the Company.

The Company released an incentive plan on equities of A-share (draft) in April, which intended to grant 6 million restricted shares of the Company to 16 middle and senior level management personnel and key technical personnel if the yoy growth ratio of revenue is no lower than 0%, +20%, +25%, +13% and +17%, respectively from 2020 to 2024. The plan aimed at binding benefits of employees with the Company to ensure the steady and healthy growth of future results.

Investment Thesis

Considering the epidemic, we decide to revise target price to HK$7 for the Company, equivalent to 2020/2021 E 13.4/8.6x P/E, Accumulate rating. (Closing price as at 15 June 2020)

Financials

Click Here for PDF format...




Recommendation on 23-6-2020
RecommendationAccumulate
Price on Recommendation Date$ 6.100
Suggested purchase priceN/A
Target Price$ 7.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]